Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00623480 · ClinicalTrials.gov registry record · Phase 3
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
A Phase 3 study of Hemophilia A, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 84
- Enrollment target
- 20
- Study locations
NCT00623480: Completed Phase 3 study of Hemophilia A, sponsored by Bayer.
NCT00623480 is a Phase 3 study of Hemophilia A that has completed, run by Bayer. The registered enrollment target is 84 participants, roughly in line with the 90-participant average among 42 other Hemophilia A trials with a reported enrollment target. The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00623480, a Phase 3 study of Hemophilia A, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 84 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the effect of secondary prophylaxis as compared to episodic treatment on bleeding frequency (number of bleeds per year) and on joint damage.
Conditions Studied
Interventions
- BIOLOGICAL Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Study Locations (20)
California
- - Orange
- - Sacramento
Illinois
- - Chicago
- - Chicago
Arizona
- - Tucson
Arkansas
- - Little Rock
Colorado
- - Aurora
District of Columbia
- - Washington D.C.
Florida
- - Orlando
Georgia
- - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2008-03 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
What the finished NCT00623480 record still lists
NCT00623480 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 84 participants, a relatively small participant target, roughly in line with the 90-participant average among 42 other Hemophilia A trials with a reported enrollment target.
The record links to 1 condition, with Hemophilia A appearing as the primary indexed condition, and to 1 intervention - of which Recombinant Factor VIII (Kogenate FS, BAY14-2222) is the first listed.
NCT00623480 names 20 study sites across 18 states, led by California, Illinois, Arizona.
Frequently Asked Questions
What is clinical trial NCT00623480 about?
NCT00623480 is a clinical study titled "Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment". To evaluate the effect of secondary prophylaxis as compared to episodic treatment on bleeding frequency (number of bleeds per year) and on joint damage.
What is the current status of trial NCT00623480?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 84 participants. The study started on 2008-03. Estimated completion is 2013-11.
What conditions does trial NCT00623480 study?
This clinical trial studies the following conditions: Hemophilia A.
What interventions are being tested in trial NCT00623480?
The interventions under investigation include: Recombinant Factor VIII (Kogenate FS, BAY14-2222) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00623480?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00623480 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemophilia A
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00623480's enrollment target sits among peer trials
84 16th of 42 higher than 27 of 42 other Hemophilia A trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemophilia A trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia B
RECRUITING · Phase 3
-
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
RECRUITING · Phase 3
-
SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis
RECRUITING · Phase 3
-
Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02391519 · 84 participants
Effects of High Altitude on AMPK Activation
- NCT03838536 · 84 participants · NA
Synergistic Activity of Human Milk Nutrients and Infant Cognition
- NCT03884075 · 84 participants · Phase 2
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
- NCT03894917 · 84 participants
Characterizing Disease Biology, Treatment and Toxicity in Older Adults With Hepatocellular Carcinoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia